Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Concert Pharmaceutic (NQ: CNCE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Concert Pharmaceutic

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
58 Stocks Moving In Thursday's Mid-Day Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 102.6% to $0.1580 after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered direct offering. 
Via Benzinga
Concert Pharma: Q1 Earnings Insights
Concert Pharma (NASDAQ:CNCE) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
28 Stocks Moving in Thursday's Pre-Market Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 89.7% to $0.1480 in pre-market trading after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered... 
Via Benzinga
Concert Pharmaceuticals Reports First Quarter 2022 Financial Results
From Concert Pharmaceuticals, Inc.
Via Business Wire
Earnings Outlook For Concert Pharmaceuticals
Concert Pharmaceuticals (NASDAQ:CNCE) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Concert Pharma Earnings Conference Call Is Coming Up, Here's What You Need To Know
Concert Pharma (NASDAQ:CNCE) will host a conference call at 08:30 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Concert Pharma (CNCE) Conference Call Follow this link to... 
Via Benzinga
Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022
From Concert Pharmaceuticals, Inc.
Via Business Wire
Big Pharma's Sanofi Enters Licencing Agreement With Private Psychedelics Company Terran
Terran Biosciences is slowly but surely finding its place in the psychedelics industry. 
Via Benzinga
Concert Pharmaceuticals Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Concert Pharmaceuticals (NASDAQ:CNCE) reported Q4 sales of $13.00 thousand. Earnings fell to a loss of $36.13 million, resulting in a 35.43% decrease from last... 
Via Benzinga
Recap: Concert Pharmaceuticals Q4 Earnings
Concert Pharmaceuticals (NASDAQ:CNCE) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement... 
Via Benzinga
A Preview Of Concert Pharmaceuticals's Earnings
Concert Pharmaceuticals (NASDAQ:CNCE) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement.... 
Via Benzinga
Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022
From Concert Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... 
Via Benzinga
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
From Concert Pharmaceuticals, Inc.
Via Business Wire
Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference
From Concert Pharmaceuticals, Inc.
Via Business Wire
Concert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare Conferences
From Concert Pharmaceuticals, Inc.
Via Business Wire
Concert Pharmaceuticals, inc (CNCE) Q3 2021 Earnings Call Transcript
CNCE earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
How Bad Are Concert Pharmaceuticals's Earnings? | Return On Capital Employed
Benzinga Pro data, Concert Pharmaceuticals (NASDAQ:CNCE) reported Q3 sales of $543.00 thousand. Earnings fell to a loss of $26.80 million, resulting in a 530.86% decrease from... 
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
From Concert Pharmaceuticals, Inc.
Via Business Wire
81 Biggest Movers From Yesterday
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) jumped 79.8... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Evaxion Biotech (NASDAQ:EVAX) stock moved upwards by 157.5% to $16.74 during Thursday's regular session. Evaxion Biotech's stock is trading at a volume of... 
Via Benzinga
55 Stocks Moving In Thursday's Mid-Day Session
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. (NASDAQ: NRDS) jumped 60% to $28.86 after the... 
Via Benzinga
Concert Pharma Stock Surges On $65M Financing From Healthcare Funds
Concert Pharmaceuticals Inc (NASDAQ: CNCE) has agreed with BVF Partners L.P. and RA Capital Management to raise gross proceeds of $65 million. In addition,... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Evaxion Biotech (NASDAQ:EVAX) shares increased by 244.61% to $22.4 during Thursday's pre-market session. The company's market cap stands at $430.0 million... 
Via Benzinga
Concert Pharmaceuticals Announces $65 Million Financing
From Concert Pharmaceuticals, Inc.
Via Business Wire
Concert Pharmaceuticals to Report Third Quarter 2021 Results on November 9, 2021
From Concert Pharmaceuticals, Inc.
Via Business Wire
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
From Concert Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.